IL158643D0 - Use of hmg fragments as anti-inflammatory agents - Google Patents

Use of hmg fragments as anti-inflammatory agents

Info

Publication number
IL158643D0
IL158643D0 IL15864302A IL15864302A IL158643D0 IL 158643 D0 IL158643 D0 IL 158643D0 IL 15864302 A IL15864302 A IL 15864302A IL 15864302 A IL15864302 A IL 15864302A IL 158643 D0 IL158643 D0 IL 158643D0
Authority
IL
Israel
Prior art keywords
hmg
fragments
anti
use
inflammatory agents
Prior art date
Application number
IL15864302A
Original Assignee
Long Island Jewish Res Inst
Gen Hospital Corp
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US29103401P priority Critical
Application filed by Long Island Jewish Res Inst, Gen Hospital Corp, Univ Pittsburgh filed Critical Long Island Jewish Res Inst
Priority to PCT/US2002/015329 priority patent/WO2002092004A2/en
Publication of IL158643D0 publication Critical patent/IL158643D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria
    • Y02A50/412Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/485The waterborne disease being caused by a protozoa
    • Y02A50/486The waterborne disease being caused by a protozoa the protozoan being Entamoeba histolytica, i.e. Amoebiasis
    • Y02A50/487The waterborne disease being caused by a protozoa the protozoan being Entamoeba histolytica, i.e. Amoebiasis the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
IL15864302A 2001-05-15 2002-05-15 Use of hmg fragments as anti-inflammatory agents IL158643D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US29103401P true 2001-05-15 2001-05-15
PCT/US2002/015329 WO2002092004A2 (en) 2001-05-15 2002-05-15 Use of hmg fragment as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
IL158643D0 true IL158643D0 (en) 2004-05-12

Family

ID=23118552

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15864302A IL158643D0 (en) 2001-05-15 2002-05-15 Use of hmg fragments as anti-inflammatory agents
IL158643A IL158643A (en) 2001-05-15 2003-10-28 Anti-hmg monoclonal antibodies and compositions containing the same
IL208892A IL208892A (en) 2001-05-15 2010-10-24 Hmg fragments as anti-inflammatory agents

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL158643A IL158643A (en) 2001-05-15 2003-10-28 Anti-hmg monoclonal antibodies and compositions containing the same
IL208892A IL208892A (en) 2001-05-15 2010-10-24 Hmg fragments as anti-inflammatory agents

Country Status (18)

Country Link
US (2) US20030060410A1 (en)
EP (1) EP1392844A4 (en)
JP (1) JP2005512507A (en)
KR (1) KR20040018370A (en)
CN (1) CN100447154C (en)
AU (1) AU2002309829B2 (en)
BR (1) BR0209689A (en)
CA (1) CA2447576C (en)
CZ (1) CZ20033402A3 (en)
HU (1) HU0500042A3 (en)
IL (3) IL158643D0 (en)
IS (1) IS7037A (en)
MX (1) MXPA03010449A (en)
NO (1) NO20035087L (en)
NZ (1) NZ529423A (en)
PL (1) PL367132A1 (en)
SK (1) SK15422003A3 (en)
WO (1) WO2002092004A2 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7754217B2 (en) * 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) * 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7220723B2 (en) * 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US20090069227A9 (en) * 2003-04-29 2009-03-12 Capogrossi Maurizio C Use of HMGB1 to promote stem cell migration and/or proliferation
US20060035851A1 (en) * 2002-07-03 2006-02-16 Bianchi Marco E Use of hmgb1 in the treatment of tissue damage and or to promote tissue repair
US20040156851A1 (en) * 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
CA2505682A1 (en) * 2002-11-20 2004-06-03 Kevin J. Tracey Use of hmgb polypeptides for increasing immune responses
US20040141948A1 (en) * 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
EP2062595A1 (en) * 2002-12-06 2009-05-27 The Feinstein Institute for Medical Research Inhibition of inflammation using alpha 7 receptor-binding cholinergic agonists
WO2005025604A2 (en) * 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
CN1878793A (en) * 2003-09-11 2006-12-13 鉴定医疗有限公司 Monoclonal antibodies against HMGB1
EP1768698A4 (en) 2004-06-17 2009-01-28 Medimmune Inc Immunogenic compositions comprising hmgb1 polypeptides
EP1771565B1 (en) 2004-07-20 2012-09-05 The Feinstein Institute for Medical Research Rage protein derivatives
EP1814576A2 (en) * 2004-07-20 2007-08-08 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
NZ553809A (en) 2004-09-03 2010-03-26 Creabilis Therapeutics Spa Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human box-A of HMGB1 to prevent and/or antagonize pathologies induced by HMGB1
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
CN102731654A (en) 2004-10-22 2012-10-17 米迪缪尼有限公司 High affinity antibodies against hmgb1 and methods of use thereof
EP1899376A2 (en) 2005-06-16 2008-03-19 The Feinstein Institute for Medical Research Antibodies against hmgb1 and fragments thereof
EP1909834A2 (en) * 2005-07-18 2008-04-16 Critical Therapeutics, Inc. Use of hmgb1 antagonists for the treatment of inflammatory skin conditions
US20100172909A1 (en) * 2005-10-24 2010-07-08 Masahiro Nishibori Cerebral edema suppressant
JP3876325B1 (en) * 2005-10-24 2007-01-31 国立大学法人 岡山大学 Cerebral infarction inhibitor
WO2007076200A2 (en) 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof
US7829097B2 (en) * 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
JPWO2007102410A1 (en) * 2006-02-24 2009-07-23 国立大学法人金沢大学 New applications of Rage polypeptide
JP3882090B1 (en) 2006-05-19 2007-02-14 国立大学法人 岡山大学 Cerebral vasospasm inhibitor
JP2010503630A (en) * 2006-09-15 2010-02-04 クレアビリス・セラピューティクス・エスピーエー HMGB1 of Box-A and Box-A variants polymer conjugates of the HMGB1
PT2068935E (en) 2006-09-15 2011-07-08 Creabilis Therapeutics S R L Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1
JP5225109B2 (en) 2007-02-15 2013-07-03 国立大学法人 熊本大学 Therapeutic agent containing as an active ingredient an antibody that specifically binds to human HMGB-1
EP2123299A4 (en) * 2007-02-15 2011-10-05 Univ Kyushu Nat Univ Corp Therapeutic agent for interstitial pulmonary disease comprising anti-hmgb-1 antibody
WO2008099917A1 (en) * 2007-02-15 2008-08-21 Fukuoka University Agent for suppressing rejection in organ transplantation comprising anti-hmgb-1 antibody
KR20160070169A (en) 2008-04-30 2016-06-17 가부시키가이샤 제노믹스 Method for collecting functional cells in vivo with high efficiency
US8673580B2 (en) 2008-04-30 2014-03-18 Genomix Co., Ltd. Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
JP5467313B2 (en) 2009-09-28 2014-04-09 国立大学法人 岡山大学 Atherosclerosis inhibitor
US8956618B2 (en) 2010-01-21 2015-02-17 The Texas A&M University System Vaccine vectors and methods of enhancing immune responses
AU2011299025B2 (en) * 2010-09-09 2015-07-09 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
WO2012170740A2 (en) * 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
PL2913058T3 (en) 2012-10-25 2018-04-30 Genomix Co., Ltd. Novel method for treating cardiac infarction using hmgb1 fragment
TR201807769T4 (en) * 2012-10-25 2018-06-21 Genomix Co Ltd New methods for the treatment of spinal cord injury using HMGB1 fragment.
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
GB201508337D0 (en) 2015-05-15 2015-06-24 Hmgbiotech S R L Novel peptides

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US144201A (en) * 1873-11-04 Improvement in volute springs
US53841A (en) * 1866-04-10 Improvement in measuring-funnels
US60410A (en) * 1866-12-11 newman
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
WO1998002744A1 (en) * 1996-07-17 1998-01-22 Kaneka Corporation Diagnostic drugs for autoimmune diseases
JP3472048B2 (en) * 1995-10-09 2003-12-02 鐘淵化学工業株式会社 Diagnostic agent for autoimmune disease
US6323329B1 (en) * 1995-12-21 2001-11-27 Jorn Bullerdiek Nucleic acid sequences of genes encoding high mobility group proteins
US6720472B2 (en) * 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
US6171779B1 (en) * 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer
US20030032090A1 (en) * 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
US20030027260A1 (en) * 1997-10-17 2003-02-06 Genentech, Inc. Human Toll homologues
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US7151082B2 (en) * 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6677321B1 (en) * 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7754217B2 (en) * 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
US20030032674A1 (en) * 2001-08-13 2003-02-13 Hwang Daniel H. Use of unsaturated fatty acids to treat severe inflammatory diseases

Also Published As

Publication number Publication date
AU2002309829B2 (en) 2007-08-23
HU0500042A3 (en) 2010-01-28
CN1516739A (en) 2004-07-28
CN100447154C (en) 2008-12-31
BR0209689A (en) 2006-02-07
EP1392844A4 (en) 2006-09-06
HU0500042A2 (en) 2005-03-29
IL208892A (en) 2015-04-30
EP1392844A2 (en) 2004-03-03
IS7037A (en) 2003-11-14
WO2002092004A3 (en) 2003-10-09
CZ20033402A3 (en) 2004-10-13
NZ529423A (en) 2008-10-31
IL158643A (en) 2010-12-30
NO20035087D0 (en) 2003-11-14
CA2447576C (en) 2014-04-08
NO20035087L (en) 2003-12-09
MXPA03010449A (en) 2004-12-06
US20040005316A1 (en) 2004-01-08
IL208892D0 (en) 2011-07-31
KR20040018370A (en) 2004-03-03
JP2005512507A (en) 2005-05-12
CA2447576A1 (en) 2002-11-21
WO2002092004A2 (en) 2002-11-21
PL367132A1 (en) 2005-02-21
US20030060410A1 (en) 2003-03-27
SK15422003A3 (en) 2005-01-03
WO2002092004A8 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
AP1635A (en) Azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease
GB0103973D0 (en) Improvements relating to skin prickers
ZA200204020B (en) Use of anti-CTLA-4-antibodies.
HK1086488A1 (en) Compound and use thereof for the treatment of cancer
AU2002252415A1 (en) Treatment of lipid pool
IL156818D0 (en) New composition
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
HK1084114A1 (en) Compounds for synthesizing intermediate useful in the preparation of atorvastatin
TWI294875B (en) Phenylindoles for the treatment of hiv
PL371428A1 (en) Substituted indolizine-like compounds and methods of use
HK1077525A1 (en) Augentation of organ function
HU0304041A3 (en) Compounds useful as intermediates
AU2002359200A1 (en) New composition
PT1438306E (en) Derivatives of uk-2a
AU2002359163A1 (en) New use
AU2002251257A1 (en) Methods of Using O6-alkylguanine-DNA Alkyltransferases
GB0128108D0 (en) Therapeutic use
SI1392642T1 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
PL367311A1 (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease
AU2002313828A1 (en) Pharmaceutical compositions for the treatment of asthma
SI2092935T1 (en) Pharmaceutical compositions for the treatment of asthma
HK1055110A1 (en) Preparation of trimethylolpropane
HU0401248A3 (en) Preparation of aminopyrimidine compounds and new intermediates
GB2383536B (en) Pharmaceutical Composition
AU2002329569A1 (en) Non-invasive glucose-meter